Zolpidem
Ambien, Edluar, Zolpidem (zolpidem) is a small molecule pharmaceutical. Zolpidem was first approved as Ambien on 1992-12-16. It is used to treat sleep initiation and maintenance disorders in the USA. The pharmaceutical is active against gamma-aminobutyric acid receptor subunit alpha-1. In addition, it is known to target gamma-aminobutyric acid receptor subunit alpha-2 and gamma-aminobutyric acid receptor subunit alpha-3.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| nervous system diseases | D009422 |
| mental disorders | D001523 |
Trade Name
FDA
EMA
Ambien, Edluar (generic drugs available since 2007-04-23, discontinued: Intermezzo, Tovalt, Zolpimist)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| gabazolpidem-5 | unapproved drug other | 2011-08-01 |
| sentrazolpidem pm-5 | unapproved drug other | 2011-08-01 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| sleep initiation and maintenance disorders | — | D007319 | F51.01 |
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Zolpidem Tartrate, Zolpimist, Aytu | |||
| 8236285 | 2032-08-07 | DS, DP | U-70 |
| Zolpidem Tartrate, Edluar, Mylan Speciality Lp | |||
| 9265720 | 2031-02-25 | U-674 | |
| 9597281 | 2027-04-06 | U-674 | |
| Zolpidem Tartrate, Intermezzo, Purdue Pharma | |||
| 8242131 | 2029-08-20 | U-1266 | |
| 7658945 | 2027-04-15 | DP | U-1194 |
| 7682628 | 2025-02-16 | U-1194 | |
| 8252809 | 2025-02-16 | DP | |
HCPCS
No data
Clinical
Clinical Trials
140 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Sleep initiation and maintenance disorders | D007319 | — | F51.01 | 8 | 13 | 18 | 19 | 8 | 62 |
| Healthy volunteers/patients | — | — | — | 13 | 1 | — | 2 | 4 | 19 |
| Sleep wake disorders | D012893 | — | G47 | 1 | 1 | 2 | 4 | 4 | 11 |
| Sleep | D012890 | GO_0030431 | — | 1 | 1 | 1 | 2 | 3 | 8 |
| Depression | D003863 | — | F33.9 | 1 | — | 1 | 3 | — | 5 |
| Heart failure | D006333 | HP_0001635 | I50 | — | — | — | 1 | 2 | 3 |
| Sleep apnea syndromes | D012891 | HP_0010535 | G47.3 | — | — | — | 2 | — | 2 |
| Aging | D000375 | GO_0007568 | R41.81 | — | — | — | 1 | 1 | 2 |
| Obstructive sleep apnea | D020181 | EFO_0003918 | G47.33 | — | — | — | 2 | — | 2 |
| Psychomotor disorders | D011596 | — | — | — | — | — | 1 | — | 1 |
Show 8 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Attention deficit disorder with hyperactivity | D001289 | EFO_0003888 | F90 | — | — | 1 | — | 1 | 2 |
| Dementia | D003704 | EFO_0003862 | F03 | — | — | 1 | — | 1 | 2 |
| Schizophrenia | D012559 | EFO_0000692 | F20 | — | — | 1 | — | 1 | 2 |
| Alzheimer disease | D000544 | EFO_0000249 | F03 | — | — | 1 | — | 1 | 2 |
| Substance-related disorders | D019966 | EFO_0003890 | F13 | — | 1 | 1 | — | 1 | 2 |
| Psychophysiologic disorders | D011602 | — | F45.9 | — | — | 1 | — | — | 1 |
| Anxiety disorders | D001008 | EFO_0006788 | F41.1 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Parkinson disease | D010300 | EFO_0002508 | G20 | — | 2 | — | — | — | 2 |
| Autistic disorder | D001321 | HP_0000717 | F84.0 | — | 1 | — | — | 1 | 2 |
| Consciousness disorders | D003244 | — | — | — | 1 | — | — | — | 1 |
| Burns | D002056 | — | T30.0 | — | 1 | — | — | — | 1 |
| Low back pain | D017116 | HP_0003419 | M54.5 | 1 | 1 | — | — | — | 1 |
| Autism spectrum disorder | D000067877 | HP_0000729 | F84.0 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Dystonic disorders | D020821 | — | G24 | 1 | — | — | — | — | 1 |
| Marijuana abuse | D002189 | EFO_0007191 | F12 | 1 | — | — | — | — | 1 |
| Prostatic neoplasms | D011471 | — | C61 | 1 | — | — | — | — | 1 |
| Obesity | D009765 | EFO_0001073 | E66.9 | 1 | — | — | — | — | 1 |
| Therapeutic equivalency | D013810 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pain | D010146 | EFO_0003843 | R52 | — | — | — | — | 3 | 3 |
| Hypertension | D006973 | EFO_0000537 | I10 | — | — | — | — | 2 | 2 |
| Menorrhagia | D008595 | EFO_0003945 | N92.0 | — | — | — | — | 2 | 2 |
| Hemophilia a | D006467 | EFO_0007267 | D66 | — | — | — | — | 2 | 2 |
| Pneumonia | D011014 | EFO_0003106 | — | — | — | — | — | 2 | 2 |
| Hyperaldosteronism | D006929 | HP_0011736 | E26 | — | — | — | — | 2 | 2 |
| Pulmonary arterial hypertension | D000081029 | — | — | — | — | — | — | 2 | 2 |
| Urinary tract infections | D014552 | EFO_0003103 | N39.0 | — | — | — | — | 2 | 2 |
| Hypokalemia | D007008 | HP_0002900 | E87.6 | — | — | — | — | 2 | 2 |
| Cardiac arrhythmias | D001145 | EFO_0004269 | I49.9 | — | — | — | — | 2 | 2 |
Show 47 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Zolpidem |
| INN | zolpidem |
| Description | Zolpidem is an imidazo[1,2-a]pyridine compound having a 4-tolyl group at the 2-position, an N,N-dimethylcarbamoylmethyl group at the 3-position and a methyl substituent at the 6-position. It has a role as a central nervous system depressant, a GABA agonist and a sedative. |
| Classification | Small molecule |
| Drug class | hypnotics/sedatives (zolpidem type) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | Cc1ccc(-c2nc3ccc(C)cn3c2CC(=O)N(C)C)cc1 |
Identifiers
| PDB | — |
| CAS-ID | 82626-48-0 |
| RxCUI | — |
| ChEMBL ID | CHEMBL911 |
| ChEBI ID | 10125 |
| PubChem CID | 5732 |
| DrugBank | DB00425 |
| UNII ID | 7K383OQI23 (ChemIDplus, GSRS) |
Target
Agency Approved
GABRA1
GABRA1
Organism
Homo sapiens
Gene name
GABRA1
Gene synonyms
NCBI Gene ID
Protein name
gamma-aminobutyric acid receptor subunit alpha-1
Protein synonyms
GABA(A) receptor subunit alpha-1, GABA(A) receptor, alpha 1, gamma-aminobutyric acid (GABA) A receptor, alpha 1, gamma-aminobutyric acid type A receptor alpha1 subunit
Uniprot ID
Mouse ortholog
Gabra1 (14394)
gamma-aminobutyric acid receptor subunit alpha-1 (P62812)
Alternate
GABRA2
GABRA2
GABRA3
GABRA3
Organism
Homo sapiens
Gene name
GABRA2
Gene synonyms
NCBI Gene ID
Protein name
gamma-aminobutyric acid receptor subunit alpha-2
Protein synonyms
GABA(A) receptor subunit alpha-2, gamma-aminobutyric acid type A receptor alpha2 subunit
Uniprot ID
Mouse ortholog
Gabra2 (14395)
gamma-aminobutyric acid receptor subunit alpha-2 (P26048)
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
No data
Estimated US medical usage
Zolpidem
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 8,840 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
33,291 adverse events reported
View more details
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use